Exploring the effect of deucravacitinib in patients with palmoplantar pustular psoriasis.

IF 2.9 4区 医学 Q2 DERMATOLOGY
David A De Luca,Cristian Papara,Tomasz Hawro,Diamant Thaçi,Sascha Ständer
{"title":"Exploring the effect of deucravacitinib in patients with palmoplantar pustular psoriasis.","authors":"David A De Luca,Cristian Papara,Tomasz Hawro,Diamant Thaçi,Sascha Ständer","doi":"10.1080/09546634.2024.2399220","DOIUrl":null,"url":null,"abstract":"INTRODUCTION\r\nPalmoplantar pustular psoriasis (PPPP) is a chronic inflammatory skin disorder characterized by sterile pustules on the palms and soles, significantly impacting patients' quality of life. The pathogenesis of PPPP involves intricate interactions between immune dysregulation, environmental triggers, and genetic predisposition. The treatment of PPPP is challenging, and there is a need for effective and safe treatment options for patients.\r\n\r\nOBJECTIVE\r\nWe evaluated the efficacy and safety of deucravacitinib, a novel oral selective allosteric inhibitor of tyrosine kinase 2 (TYK2), in treating refractory PPPP.\r\n\r\nMATERIAL AND METHODS\r\nA retrospective analysis was conducted on five patients treated with deucravacitinib 6 mg/day, with clinical assessments at weeks 0, 4, and 16.\r\n\r\nRESULTS\r\nWhile initial worsening was observed in most patients, three showed improvement by week 16. One patient improved with the addition of methotrexate. Treatment was discontinued in two patients after week 16. Adverse effects were primarily viral and bacterial infections, and no serious adverse events occurred.\r\n\r\nCONCLUSION\r\nCurrent therapeutic options for PPPP are limited, necessitating exploration of novel treatments. Deucravacitinib's mechanism of action, targeting TYK2, could show promise in PPPP management. However, its efficacy and safety in this specific condition require further investigation through larger, randomized controlled trials.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Dermatological Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09546634.2024.2399220","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

INTRODUCTION Palmoplantar pustular psoriasis (PPPP) is a chronic inflammatory skin disorder characterized by sterile pustules on the palms and soles, significantly impacting patients' quality of life. The pathogenesis of PPPP involves intricate interactions between immune dysregulation, environmental triggers, and genetic predisposition. The treatment of PPPP is challenging, and there is a need for effective and safe treatment options for patients. OBJECTIVE We evaluated the efficacy and safety of deucravacitinib, a novel oral selective allosteric inhibitor of tyrosine kinase 2 (TYK2), in treating refractory PPPP. MATERIAL AND METHODS A retrospective analysis was conducted on five patients treated with deucravacitinib 6 mg/day, with clinical assessments at weeks 0, 4, and 16. RESULTS While initial worsening was observed in most patients, three showed improvement by week 16. One patient improved with the addition of methotrexate. Treatment was discontinued in two patients after week 16. Adverse effects were primarily viral and bacterial infections, and no serious adverse events occurred. CONCLUSION Current therapeutic options for PPPP are limited, necessitating exploration of novel treatments. Deucravacitinib's mechanism of action, targeting TYK2, could show promise in PPPP management. However, its efficacy and safety in this specific condition require further investigation through larger, randomized controlled trials.
探索德拉瓦替尼对掌跖脓疱型银屑病患者的疗效。
引言 掌跖脓疱性银屑病(PPPP)是一种慢性炎症性皮肤病,以手掌和足底出现无菌性脓疱为特征,严重影响患者的生活质量。脓疱型银屑病的发病机制涉及免疫调节失调、环境诱因和遗传易感性之间错综复杂的相互作用。我们评估了新型口服酪氨酸激酶 2(TYK2)选择性异位抑制剂 deucravacitinib 治疗难治性 PPPP 的疗效和安全性。材料和方法对5名接受6毫克/天德拉瓦替尼治疗的患者进行了回顾性分析,并在第0周、第4周和第16周进行了临床评估。结果虽然大多数患者的病情最初都有所恶化,但有3名患者的病情在第16周时有所改善。一名患者在加用甲氨蝶呤后病情有所好转。两名患者在第 16 周后停止了治疗。不良反应主要是病毒和细菌感染,没有发生严重不良事件。Deucravacitinib以TYK2为靶点的作用机制有望用于PPPP的治疗。然而,它在这种特殊情况下的疗效和安全性还需要通过更大规模的随机对照试验来进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.50
自引率
0.00%
发文量
145
审稿时长
6-12 weeks
期刊介绍: The Journal of Dermatological Treatment covers all aspects of the treatment of skin disease, including the use of topical and systematically administered drugs and other forms of therapy. The Journal of Dermatological Treatment is positioned to give dermatologists cutting edge information on new treatments in all areas of dermatology. It also publishes valuable clinical reviews and theoretical papers on dermatological treatments.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信